1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Knee Cartilage Repair Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Knee Cartilage Repair Market Analysis and Forecasts, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Biologicals Used in Knee Cartilage Repair
5.3. COVID-19 Pandemic Impact on Industry
6. Knee Cartilage Repair Market Analysis and Forecast, by Application
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Application, 2023–2031
6.3.1. Arthroscopic Chondroplasty
6.3.2. Autologous Chondrocyte Implantation
6.3.3. Osteochondral Graft Transplantation
6.3.4. Cell-based Cartilage Resurfacing
6.3.5. Implant Transplant
6.3.6. Microfracture
6.3.7. Others
6.4. Market Attractiveness, by Application
7. Global Knee Cartilage Repair Market Analysis and Forecast, by End-user
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023–2031
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Orthopedic Clinics
7.3.4. Others
7.4. Market Attractiveness, by End-user
8. Global Knee Cartilage Repair Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Knee Cartilage Repair Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Application, 2023–2031
9.2.1. Arthroscopic Chondroplasty
9.2.2. Autologous Chondrocyte Implantation
9.2.3. Osteochondral Graft Transplantation
9.2.4. Cell-based Cartilage Resurfacing
9.2.5. Implant Transplant
9.2.6. Microfracture
9.2.7. Others
9.3. Market Value Forecast, by End-user, 2023–2031
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Orthopedic Clinics
9.3.4. Others
9.4. Market Value Forecast, by Country, 2023–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By End-user
9.5.3. By Country
10. Europe Knee Cartilage Repair Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Application, 2023–2031
10.2.1. Arthroscopic Chondroplasty
10.2.2. Autologous Chondrocyte Implantation
10.2.3. Osteochondral Graft Transplantation
10.2.4. Cell-based Cartilage Resurfacing
10.2.5. Implant Transplant
10.2.6. Microfracture
10.2.7. Others
10.3. Market Value Forecast, by End-user, 2023–2031
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Orthopedic Clinics
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Knee Cartilage Repair Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Application, 2023–2031
11.2.1. Arthroscopic Chondroplasty
11.2.2. Autologous Chondrocyte Implantation
11.2.3. Osteochondral Graft Transplantation
11.2.4. Cell-based Cartilage Resurfacing
11.2.5. Implant Transplant
11.2.6. Microfracture
11.2.7. Others
11.3. Market Value Forecast, by End-user, 2023–2031
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Orthopedic Clinics
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Knee Cartilage Repair Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Application, 2023–2031
12.2.1. Arthroscopic Chondroplasty
12.2.2. Autologous Chondrocyte Implantation
12.2.3. Osteochondral Graft Transplantation
12.2.4. Cell-based Cartilage Resurfacing
12.2.5. Implant Transplant
12.2.6. Microfracture
12.2.7. Others
12.3. Market Value Forecast, by End-user, 2023–2031
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Orthopedic Clinics
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Knee Cartilage Repair Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application, 2023–2031
13.2.1. Arthroscopic Chondroplasty
13.2.2. Autologous Chondrocyte Implantation
13.2.3. Osteochondral Graft Transplantation
13.2.4. Cell-based Cartilage Resurfacing
13.2.5. Implant Transplant
13.2.6. Microfracture
13.2.7. Others
13.3. Market Value Forecast, by End-user, 2023–2031
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Orthopedic Clinics
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Zimmer Biomet Holdings, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Smith & Nephew PLC
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Histogenics Corporation
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Medipost Co. Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. TiGenix NV
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. DePuy Synthes
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Vericel Corporation
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Stryker Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. B. Braun Melsungen AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. ISTO Technologies Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Osiris Therapeutics, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
